Investigating the effect of Valeriana officinalis extract on echocardiographic, laboratory and clinical parameters in patients with heart failure with reduced ejection fraction

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250405065212N1

Enrollment

Registered

2025-04-19

Start date

2025-04-21

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Left ventricular failure. Left ventricular failure

Interventions

Intervention 1: Intervention group: Using tablet containing 400 mg of Valeriana officinalis hydroalcoholic extract administered once daily + standard heart failure therapy. Intervention 2: Control gro

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age = 18 years Diagnosis of heart failure with systolic dysfunction Provision of informed consent for study participation

Exclusion criteria

Exclusion criteria: Class IV heart failure according to the New York Heart Association (NYHA) criteria History of renal dysfunction (GFR 3 × ULN) Severe underweight (BMI = 18.5 kg/m²) Use of warfarin, lithium, or chemotherapeutic agents Pregnancy or suspected pregnancy Other underlying conditions or comorbidities, including active infections, major surgeries, type 1 diabetes, pituitary or adrenal insufficiency, malnutrition, substance abuse or dependence, gastrointestinal disorders, or malignancy. Occurrence of a serious adverse event during the study (e.g., hypersensitivity reaction) Patient withdrawal of consent Unwillingness to continue participation

Design outcomes

Primary

Measure	Time frame
Echocardiographic parameters (LVEF, RV strain, PAP, RV diameter). Timepoint: Before intervention and 3 month after intervention. Method of measurement: Echocardiography.	—

Secondary

Measure	Time frame
CHFQOLQ-20(Congestive Heart Failure Quality of Life Questionnaire (20-item version)) questionnaire. Timepoint: Before intervention and 3 month after intervention. Method of measurement: Completion of questionnaires.;Laboratory parameters (CBC, CRP, Chol, TG, LDH, ALT, AST, uric acid). Timepoint: Before intervention and 3 month after intervention. Method of measurement: measured from fasting venous blood using standardized automated analyzers.	—

Measure

Time frame

CHFQOLQ-20(Congestive Heart Failure Quality of Life Questionnaire (20-item version)) questionnaire. Timepoint: Before intervention and 3 month after intervention. Method of measurement: Completion of questionnaires.;Laboratory parameters (CBC, CRP, Chol, TG, LDH, ALT, AST, uric acid). Timepoint: Before intervention and 3 month after intervention. Method of measurement: measured from fasting venous blood using standardized automated analyzers.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactParnian Salehi

Mashhad University of Medical Sciences

salehip4011@mums.ac.ir+98 51 3840 0001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026